Clinical trial

Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00246753

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record lapatinib ditosylate Normalized identity: lapatinib ditosylateView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2005-10-01

PhasePHASE2

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

lapatinib ditosylateDRUG · verified · RxNorm: lapatinib ditosylate

Sponsors & collaborators

UNC Lineberger Comprehensive Cancer Centerlead sponsor

GlaxoSmithKlinecollaborator

Mapped research locations

DurhamNorth Carolina, United States1 Chapel HillNorth Carolina, United States1 RaleighNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00246753 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.